Cargando…
The diverse arsenal of type III CRISPR–Cas-associated CARF and SAVED effectors
Type III CRISPR–Cas systems make use of a multi-subunit effector complex to target foreign (m)RNA transcripts complementary to the guide/CRISPR RNA (crRNA). Base-pairing of the target RNA with specialized regions in the crRNA not only triggers target RNA cleavage, but also activates the characterist...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Portland Press Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9704534/ https://www.ncbi.nlm.nih.gov/pubmed/36282000 http://dx.doi.org/10.1042/BST20220289 |
_version_ | 1784840075609112576 |
---|---|
author | Steens, Jurre A. Salazar, Carl Raymund P. Staals, Raymond H.J. |
author_facet | Steens, Jurre A. Salazar, Carl Raymund P. Staals, Raymond H.J. |
author_sort | Steens, Jurre A. |
collection | PubMed |
description | Type III CRISPR–Cas systems make use of a multi-subunit effector complex to target foreign (m)RNA transcripts complementary to the guide/CRISPR RNA (crRNA). Base-pairing of the target RNA with specialized regions in the crRNA not only triggers target RNA cleavage, but also activates the characteristic Cas10 subunit and sets in motion a variety of catalytic activities that starts with the production of cyclic oligoadenylate (cOA) second messenger molecules. These messenger molecules can activate an extensive arsenal of ancillary effector proteins carrying the appropriate sensory domain. Notably, the CARF and SAVED effector proteins have been responsible for renewed interest in type III CRISPR–Cas due to the extraordinary diversity of defenses against invading genetic elements. Whereas only a handful of CARF and SAVED proteins have been studied so far, many of them seem to provoke abortive infection, aimed to kill the host and provide population-wide immunity. A defining feature of these effector proteins is the variety of in silico-predicted catalytic domains they are fused to. In this mini-review, we discuss all currently characterized type III-associated CARF and SAVED effector proteins, highlight a few examples of predicted CARF and SAVED proteins with interesting predicted catalytic activities, and speculate how they could contribute to type III immunity. |
format | Online Article Text |
id | pubmed-9704534 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Portland Press Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97045342022-12-06 The diverse arsenal of type III CRISPR–Cas-associated CARF and SAVED effectors Steens, Jurre A. Salazar, Carl Raymund P. Staals, Raymond H.J. Biochem Soc Trans Review Articles Type III CRISPR–Cas systems make use of a multi-subunit effector complex to target foreign (m)RNA transcripts complementary to the guide/CRISPR RNA (crRNA). Base-pairing of the target RNA with specialized regions in the crRNA not only triggers target RNA cleavage, but also activates the characteristic Cas10 subunit and sets in motion a variety of catalytic activities that starts with the production of cyclic oligoadenylate (cOA) second messenger molecules. These messenger molecules can activate an extensive arsenal of ancillary effector proteins carrying the appropriate sensory domain. Notably, the CARF and SAVED effector proteins have been responsible for renewed interest in type III CRISPR–Cas due to the extraordinary diversity of defenses against invading genetic elements. Whereas only a handful of CARF and SAVED proteins have been studied so far, many of them seem to provoke abortive infection, aimed to kill the host and provide population-wide immunity. A defining feature of these effector proteins is the variety of in silico-predicted catalytic domains they are fused to. In this mini-review, we discuss all currently characterized type III-associated CARF and SAVED effector proteins, highlight a few examples of predicted CARF and SAVED proteins with interesting predicted catalytic activities, and speculate how they could contribute to type III immunity. Portland Press Ltd. 2022-10-31 2022-10-25 /pmc/articles/PMC9704534/ /pubmed/36282000 http://dx.doi.org/10.1042/BST20220289 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY) (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Review Articles Steens, Jurre A. Salazar, Carl Raymund P. Staals, Raymond H.J. The diverse arsenal of type III CRISPR–Cas-associated CARF and SAVED effectors |
title | The diverse arsenal of type III CRISPR–Cas-associated CARF and SAVED effectors |
title_full | The diverse arsenal of type III CRISPR–Cas-associated CARF and SAVED effectors |
title_fullStr | The diverse arsenal of type III CRISPR–Cas-associated CARF and SAVED effectors |
title_full_unstemmed | The diverse arsenal of type III CRISPR–Cas-associated CARF and SAVED effectors |
title_short | The diverse arsenal of type III CRISPR–Cas-associated CARF and SAVED effectors |
title_sort | diverse arsenal of type iii crispr–cas-associated carf and saved effectors |
topic | Review Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9704534/ https://www.ncbi.nlm.nih.gov/pubmed/36282000 http://dx.doi.org/10.1042/BST20220289 |
work_keys_str_mv | AT steensjurrea thediversearsenaloftypeiiicrisprcasassociatedcarfandsavedeffectors AT salazarcarlraymundp thediversearsenaloftypeiiicrisprcasassociatedcarfandsavedeffectors AT staalsraymondhj thediversearsenaloftypeiiicrisprcasassociatedcarfandsavedeffectors AT steensjurrea diversearsenaloftypeiiicrisprcasassociatedcarfandsavedeffectors AT salazarcarlraymundp diversearsenaloftypeiiicrisprcasassociatedcarfandsavedeffectors AT staalsraymondhj diversearsenaloftypeiiicrisprcasassociatedcarfandsavedeffectors |